Logo

Cardiff Oncology Reports First Patient Dosing in P-II Trial for Onvansertib + Irinotecan and 5-FU as a 2L Treatment for Metastatic Pancreatic Ductal Adenocarcinoma

Share this
Cardiff Oncology Reports First Patient Dosing in P-II Trial for Onvansertib + Irinotecan and 5-FU as a 2L Treatment for Metastatic Pancreatic Ductal Adenocarcinoma

Cardiff Oncology Reports First Patient Dosing in P-II Trial for Onvansertib + Irinotecan and 5-FU as a 2L Treatment for Metastatic Pancreatic Ductal Adenocarcinoma

Shots:

  • The first patient has been dosed in a P-II study evaluating the safety & preliminary efficacy of onvansertib + Irinotecan and 5-FU in ~40 patients as a 2L treatment for metastatic PDAC who have failed 1L gemcitabine-based therapy across 6 sites in the US
  • The 1EPs of the study is ORR and 2EPs include DoR- m-OS- ORR in patients receiving more than two treatment cycles- DCS- and assessment of KRAS allelic burden in liquid biopsies as measured by ctDNA
  • The ongoing P-II trial of onvansertib + irinotecan and 5-FU for KRAS-mutated mCRC showed clinical benefit and improve outcomes. Additionally- the company is also expected the similar results in PDAC trial

  | Ref: PR Newswire | Image: Cardiff Oncology

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions